Holen Sie sich die Stockscreener-App
10.08
0.40%
0.0581
Design Therapeutics Inc Aktie (DSGN) Neueste Nachrichten
Aug Breakouts: Can Design Therapeutics Inc expand its profit margins2026 Spike Watch & Short-Term Trading Opportunity Alerts - baoquankhu1.vn
Design Therapeutics (NASDAQ:DSGN) Stock Price Up 6.7% After Analyst Upgrade - MarketBeat
Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS), Design Therapeutics (DSGN) and Cartesian Therapeutics (RNAC) - The Globe and Mail
Piper Sandler reiterates Overweight on Design Therapeutics stock - Investing.com South Africa
Design Therapeutics, Inc. 2025 Annual Report: GeneTAC® Platform, Genomic Medicine Strategy, and Pipeline Overview - Minichart
Royal Bank Of Canada Forecasts Strong Price Appreciation for Design Therapeutics (NASDAQ:DSGN) Stock - MarketBeat
RBC Capital raises Design Therapeutics stock price target on programs - Investing.com
Design Therapeutics (NASDAQ:DSGN) Rare Disease Research In Nasdaq Today - Kalkine Media
Design Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Updates - Bitget
Design Therapeutics (NASDAQ:DSGN) Announces Earnings Results - MarketBeat
Design Therapeutics Provides Update on Clinical Trials and Financial Position for 2025 - Quiver Quantitative
Design Therapeutics reports lower-than-expected Q4 net loss - TradingView
DSGN: Net loss rose to $69.8M in 2025 as R&D spending increased; $219.8M cash at year-end - TradingView
Three genetic disease trials push ahead at Design Therapeutics - Stock Titan
Stock Report: Is Design Therapeutics Inc currently under institutional pressureJuly 2025 Selloffs & Risk Controlled Daily Trade Plans - baoquankhu1.vn
Design Therapeutics Inc expected to post a loss of 35 cents a shareEarnings Preview - TradingView
Edgewise Therapeutics, Inc. (EWTX) Stock Price, News, Quote & History - Yahoo Finance
Earnings Risk: Will Design Therapeutics Inc benefit from green energy policies2025 Big Picture & Daily Entry Point Trade Alerts - baoquankhu1.vn
Antiverse Raises $9.3M Series A to Develop Antibodies for Undruggable Disease Targets and Announces Research Agreement with the Cystic Fibrosis Foundation - Business Wire
Design Therapeutics (DSGN) Expected to Announce Quarterly Earnings on Monday - MarketBeat
DSGNDesign Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan
Design Therapeutics Highlights GeneTAC Pipeline, FA Data Timeline and DM1 Dosing Plans at Oppenheimer Conference - Defense World
Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA), Kymera Therapeutics (KYMR) and Argenx Se (ARGX) - The Globe and Mail
DSGN.O Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
DSGN Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Fuchs Dystrophy Pipeline 2026: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Kowa Pharma, Trefoil Therapeutics, Design Therapeutics, Emmecell, Santen - Barchart.com
Stock List: Research Stocks from Around the World - GuruFocus
DSGN: Clinical-stage genetic medicine programs in FA, FECD, and DM1 advance toward key data readouts - TradingView
Design Therapeutics (NASDAQ:DSGN) Hits New 1-Year HighWhat's Next? - MarketBeat
LEVI & KORSINSKY, LLP INVESTIGATING ALLEGED CLINICAL TRIAL DESIGN DEFICIENCIES AT VISTAGEN THERAPEUTICS -- CLASS ACTION FILED - PR Newswire
Absci to Report Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results on March 24, 2026 - The Manila Times
K36 Therapeutics Highlights First-in-Human KTX-2001 Prostate Cancer Study Design at American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2026 - PR Newswire
DSGN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Seaport Therapeutics Presents New Meta-Analysis Examining the Impact of Clinical Trial Design Factors on Placebo Response in Generalized Anxiety Disorder Trials - Business Wire
Brokerages Set Design Therapeutics, Inc. (NASDAQ:DSGN) Target Price at $15.00 - Defense World
Design Therapeutics (NASDAQ:DSGN) Sees Strong Trading VolumeShould You Buy? - MarketBeat
Ideas Watch: Can Design Therapeutics Inc expand its profit margins2025 Trading Recap & Capital Protection Trade Alerts - baoquankhu1.vn
RSI Check: Is Trinseo PLC a potential multi baggerBond Market & Breakout Confirmation Alerts - baoquankhu1.vn
Design Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference - Bitget
Biotech Design Therapeutics to brief investors at two healthcare events - Stock Titan
Short Interest in Design Therapeutics, Inc. (NASDAQ:DSGN) Drops By 14.0% - MarketBeat
Design Therapeutics, Inc. (NASDAQ:DSGN) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Will Design Therapeutics Inc. stock recover after earningsJuly 2025 Sentiment & Fast Exit and Entry Trade Guides - mfd.ru
Design Therapeutics (NASDAQ:DSGN) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Is Design Therapeutics Inc. stock influenced by commodity pricesJuly 2025 Earnings & Verified Chart Pattern Signals - mfd.ru
Trading Action: What is the long term forecast for Design Therapeutics Inc stockDip Buying & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
Retail Surge: Is Design Therapeutics Inc attractive for institutional investorsJuly 2025 Catalysts & Expert-Curated Trade Recommendations - baoquankhu1.vn
Galux Raises $29M Series B to Advance AI-Driven Protein Design for Drug Discovery - Business Wire
Design Therapeutics Approaches Key Clinical Milestones with Ample Funding - AD HOC NEWS
Published on: 2026-02-07 15:17:14 - baoquankhu1.vn
Is Design Therapeutics Inc. stock near bottom after decline2025 Market WrapUp & AI Powered Buy/Sell Recommendations - mfd.ru
Generate Biomedicines, Clinical-Stage Generative Biology Company Designing AI-Engineered Protein Therapeutics, Files for Nasdaq IPO - TradingView
Design Therapeutics (NASDAQ:DSGN) Shares Gap Up – Here’s Why - Defense World
Published on: 2026-02-01 06:18:16 - baoquankhu1.vn
0.18%
0.28%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):